Who
Alexander Azoy
Chief Accounting Officer
Company insider
Files Form 4 as: Chief Accounting Officer, Arcus Biosciences; Officer, Unity Biotechnology; Chief Financial Officer, Sienna Biopharmaceuticals.
In numbers
- Trades disclosed
- 49
- Buys
- 0
- Sells
- 12
- Bought
- $0
- Sold
- $650K
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 1 Apr 2019
- Last trade
- 21 Aug 2026
- Last filed
- 24 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 Aug 2026filed 24 Aug 2026 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Code M | $44K2,827 at $15.44 | filing |
| 21 Aug 2026filed 24 Aug 2026 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Sold | $85K2,827 at $30.00 | filing |
| 21 Aug 2026filed 24 Aug 2026 | RCUS Arcus Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,827 at $0.00 | filing |
| 21 Aug 2026filed 24 Aug 2026 | RCUS Arcus Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,827 at $0.00 | filing |
| 21 Aug 2026filed 24 Aug 2026 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Code M | $44K2,827 at $15.44 | filing |
| 21 Aug 2026filed 24 Aug 2026 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Sold | $85K2,827 at $30.00 | filing |
| 1 Jun 2026filed 1 Jun 2026 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Sold | $66K2,562 at $25.77 | filing |
| 1 Jun 2026filed 1 Jun 2026 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Sold | $66K2,562 at $25.77 | filing |
| 23 Jan 2026filed 26 Jan 2026 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Code A | —21,050 at $0.00 | filing |
| 23 Jan 2026filed 26 Jan 2026 | RCUS Arcus Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,050 at $0.00 | filing |
| 23 Jan 2026filed 26 Jan 2026 | RCUS Arcus Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,050 at $0.00 | filing |
| 23 Jan 2026filed 26 Jan 2026 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Code A | —21,050 at $0.00 | filing |
| 18 Dec 2025filed 18 Dec 2025 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Sold | $97K4,343 at $22.25 | filing |
| 17 Dec 2025filed 18 Dec 2025 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Sold | $47K2,113 at $22.16 | filing |
| 16 Dec 2025filed 18 Dec 2025 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Sold | $52K2,376 at $21.88 | filing |
| 26 Nov 2025filed 1 Dec 2025 | RCUS Arcus Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,900 at $0.00 | filing |
| 26 Nov 2025filed 1 Dec 2025 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Code M | $25K1,900 at $13.33 | filing |
| 26 Nov 2025filed 1 Dec 2025 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Sold | $49K1,900 at $26.00 | filing |
| 29 Sep 2025filed 30 Sep 2025 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Sold | $37K2,831 at $13.00 | filing |
| 5 Sep 2025filed 5 Sep 2025 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Sold | $19K1,579 at $11.88 | filing |
News
Arcus Biosciences (NYSE:RCUS) Price Target Raised to $41.00RCUS · dailypolitical.com · 24 Oct 2026Arcus Biosciences Dips, But Recovers From Steep Losses, On Merck-Rivaling Cancer DataRCUS · investors.com · 20 Oct 2026Invivyd (NASDAQ:IVVD) and Arcus Biosciences (NYSE:RCUS) Critical ContrastRCUS · themarketsdaily.com · 19 Oct 2026
0 headlines in the last 90 days name Alexander Azoy; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.